1800 244 735

Helpline (02) 9874 9777

Ten golden rules for reading a scientific news story

Real progress is being made on the road to Huntington’s disease treatments, but sometimes it feels like scientists promise more than they can deliver. So, HDBuzz has come up with ten ‘golden rules’ to help you decide whether a news story or press release offers genuine promise for HD, or whether its claims should be taken with a pinch of salt.

Snowflakes and glaciers

HDBuzz loves science. In our more philosophical moments, we like to imagine all the world’s scientific research as a flurry of snowflakes, gently settling on a mountain top and gradually, over months, years, and decades, compacting into a huge, unstoppable glacier that can carve entire mountains.

No single snowflake could do that, but combined, over time, the power of science to change the world – and improve the lives of people with HD – is immense.

How science reaches the public

Science becomes ‘official’ when an article about a piece of research is published in a peer-reviewed scientific journal. But a lot of science reaches the public through press releases.

Increasing competition over scarce funding means that getting results published in a scientific journal may not be enough for scientists to keep their work going.

The agencies that fund science take their lead from the public, so one way for researchers to secure funding is to get the public excited about their research. So when a piece of work has so far only focused on a small area, one way to excite people is to get them to imagine the whole glacier, rather than just the snowflake.

So, universities and research companies have press offices, whose job is to encourage scientists to produce press releases, in which they often speculate about what applications their work may have, down the line.

Of course, part of what science is for is to come up with real-world uses for new discoveries. But it’s a two edged sword, because many things that might happen, never do.

Another layer of speculation can get added, when press releases are turned by bloggers and journalists into news stories. Writing about big breakthroughs in common diseases gets more clicks and sells more papers than writing about small progress and obscure conditions.

What’s the harm?

The result can be that press releases and news articles sometimes end up promising things that the scientific research could never deliver – or which are much further away than an article suggests.

This isn’t the fault of the individual scientists, or of the press office, or the bloggers or journalists, or of the people reading the stories. Nobody sets out to mislead – but sometimes that can be the outcome, and it’s bad news because it can lead to disappointment and loss of hope.

Ten Golden Rules

The good news is that disappointment can be avoided if readers know what to look out for.

So, HDBuzz has come up with Ten Golden Rules for reading a press release or scientific news article. They’re here to help you to draw hope from scientific news where it’s warranted – and avoid being let down where it’s not.

    n

  • Be skeptical of anyone promising a “cure” for HD now, or in the near future.

  • n

  • If something sounds too good to be true, it probably is.

  • n

  • Has the research been published in a peer-reviewed scientific journal? If not, the press release may not be much more than speculation.

  • n

  • Ask yourself whether the press release is announcing the results of a project – or just the start of the project, a new partnership or funding approval. There’s a big difference.

  • n

  • The only way to show that something works in HD patients is to test it in HD patients.

  • n

  • A positive result in an animal model of HD is a very good start – but can’t be called a cure – and plenty of things that work in mice fail when tested humans.

  • n

  • Something that hasn’t been tested in an HD animal model has a very long way to go to become a treatment.

  • n

  • Your mind is like a house – it’s good to keep it open, but if you leave it wide open, you never know who’ll walk in.

  • n

  • Not sure about something you’ve read? Ask HDBuzz to write about it!

  • n

  • Finally, remember that every day, science moves us towards effective treatments for HD. Even negative results and treatment failures help us to focus on more fruitful ideas.

  • n

An example – ‘block and replace’ gene therapy

Recently, a story headed “Molecular Delivery Truck Serves Gene Therapy Cocktail” appeared on news site Science Daily. Similar articles appeared on many other sites, all reporting on work led by Prof R Jude Samulski of the University of North Carolina, and published in the journal PNAS.

The news article revealed that Samulski’s team had done something pretty impressive. The research centered on a disease called alpha-1-antitrypsin deficiency – ‘alpha-1’ for short.

People with alpha-1 develop liver problems, because they have two faulty copies of a gene that tells cells how to make the alpha 1 protein. Part of the problem is that the healthy protein is missing, and part of the problem is that the mutant protein made by cells is harmful.

Samulski’s group used a form of ‘double-barreled’ gene therapy to fix this problem in mice with the same genetic problem. First, they made a DNA-like molecule that would block production of the abnormal protein – a form of gene silencing. Then, they added a replacement gene that would be used by cells as a recipe for making the healthy protein.

They packaged these two payloads into a virus called AAV, which attaches to cells and injects its contents into them. Mice treated with the virus restored healthy levels of the alpha-1 protein and didn’t develop liver problems.

Great work – shame about the press release

Let’s be clear – this is great science and an innovative approach to a devastating illness. So what’s the problem?

Well, this research came onto our radar because the news reports about it all mentioned the potential of the approach for treating other ‘protein folding’ diseases like “cystic fibrosis, Huntington disease, amyotrophic lateral sclerosis … and Alzheimer’s disease”.

The news stories said that, because that’s what was said in a press release by the researchers themselves, and again in the PNAS article.

The trouble is, the research didn’t directly involve any of those other diseases – and huge obstacles stand in the way of it working in Huntington’s disease or the other conditions mentioned. But you wouldn’t necessarily know that from reading the news stories.

In the case of HD, there are two main problems. The first is that the huntingtin protein that causes HD is huge – seven times larger than the alpha-1 protein. The AAV virus is just too small to deliver a replacement huntingtin gene. Other viruses might be able to, but they’re not as good at delivering the cargo into cells. The other problem is that once the alpha-1 protein has been made, it’s released into the bloodstream, which means that a little goes a long way. Huntingtin protein, on the other hand, does all its work (and damage) inside cells – so any gene therapy needs to get into lots more cells in order to be beneficial.

The result of these problems is that the approach – ingenious though it is – simply can’t be applied to HD now, and even if it were radically altered, it’s unlikely it’ll benefit HD patients for at least a decade – if at all.

You might think you have to know all about gene therapy to be able to spot these problems in applying it to HD.

In fact, there are enough clues there to enable non-scientists to treat this particular breakthrough with caution, even though it might have popped up in a Google news alert for “Huntington’s disease”.

Using the golden rules

Applying our golden rules to this particular press release causes several alarm bells to ring.

Rule 2. The press release suggests that this one approach could be useful for five different, major diseases – sounds amazing … could it be too good to be true? Proceed with caution.

Rule 5. Tested in HD patients? No, this research only went as far as mice.

Rules 6 and 7. What about an HD animal model? Nope, the mice were models for alpha-1 deficiency, not Huntington’s disease.

So you don’t have to be an expert in the science of gene therapy for our rules to provoke some healthy skepticism about this particular press release.

That’s where rules 8 and 9 come in – keep an open mind but remain cautious about breakthroughs – and if you read something you’re not sure about, feel free to ask HDBuzz to investigate – either by emailing editor@hdbuzz.net or using the suggestion form at HDBuzz.net.

Rule ten

Rule ten is our favorite – because it brings us back to waxing lyrical about the snowflakes and the glacier. Rule ten is there to remind us that – whatever a particular bit of news can or can’t tell us about the search for effective treatments for Huntington’s disease – we’re a bit closer today than we were yesterday, and tomorrow we’ll be closer still.

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Updates from the EHDN Plenary Meeting 2020

Published date: 9 October, 2020

In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar event which comprised presentations on some of the latest scientific research as well as clinical studies of Huntington’s disease (HD). Researchers, doctors, patients and other interested folks, tuned in for an afternoon of talks as well as question and answer sessions to learn ... Read more Updates from the EHDN Plenary Meeting 2020

Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

Published date: 23 September, 2020

The SIGNAL clinical trial was designed to test a drug called pepinemab in people with early Huntington’s disease. The key results of that trial were recently announced, and unfortunately, pepinemab did not slow or improve HD symptoms as hoped. What was the SIGNAL trial, and who participated? The SIGNAL trial was launched in 2015 by ... Read more Sad news from the SIGNAL study: pepinemab does not influence HD symptoms

When genes are unstable: targeting somatic instability in HD

Published date: 8 September, 2020

What is somatic instability? We tend to think of DNA as a fixed blueprint, an overarching plan for the biological bricks and bridges that constitute our cells, organs, and bodies. But like any good plan, DNA is actually dynamic and adaptable. It gets frequent use as a template for creating the RNA messages that pave ... Read more When genes are unstable: targeting somatic instability in HD

Working as a team: Changes in brain development mean some brain regions may be slacking off

Published date: 17 August, 2020

The effect of the HD genetic expansion on brain development has been a hot topic in HD research. A team of researchers led by Dr. Sandrine Humbert at the Grenoble Institut Neurosciences, examined human fetal tissue to show that the mutant HD gene causes very early changes in the patterns of early brain development. But ... Read more Working as a team: Changes in brain development mean some brain regions may be slacking off

Caution urged for the use of gene-editing technology CRISPR

Published date: 12 August, 2020

A gene-editing tool known as CRISPR has been heralded as a breakthrough technology for scientists in the lab but also as a potential strategy to treat numerous genetic diseases, including Huntington’s. But a series of recent studies has suggested that CRISPR is less precise than previously thought, leading to unintended changes in the genome. Three ... Read more Caution urged for the use of gene-editing technology CRISPR

HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk

Published date: 15 July, 2020

Dopamine is an important chemical messenger in the brain that becomes imbalanced in Huntington’s disease. Researchers recently described a creative way to restore the balance and treat symptoms in HD mice, using an antihistamine drug that acts on hybrid dopamine receptors. It’s an innovative approach to HD therapeutics, but don’t start reaching for allergy meds ... Read more HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk

Welcome to our new website!

Please bear with us while we iron out the last minute wrinkles! If you have any feedback about our new site, please fill out the form below.